Indivior inks $145M Opiant buyout to add nasal opioid overdose drug to portfolio

Indivior has snapped up Opiant Pharmaceuticals for an initial $145 million, capitalizing on the fall of the company’s share price throughout the year to add a near-approval nasal formulation of nalmefene to its portfolio.